Navigation Links
Tobira Therapeutics Inc. Announces Phase I Pharmacokinetic Data of TBR-652 for the Treatment of HIV
Date:9/14/2009

PRINCETON, N.J. and SAN DIEGO, Sept. 14 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from a double-blind, placebo-controlled, multiple-dose randomized study of TBR-652 in sixty healthy volunteers. TBR-652, a CCR5 antagonist under investigation for the treatment of HIV, was evaluated at doses ranging from 25 mg once daily (QD) to 200 mg QD after a high fat meal. Pharmacokinetic parameters were measured on Days 1 and 10, while safety and tolerability were evaluated throughout the 10 day study. The results of the study demonstrate TBR-652 was well tolerated in all groups. TBR-652 reached maximum plasma exposure 3-6 hours post dose on Days 1 and 10. Mean plasma half-life ranged from 40 to 45 hours, supporting once daily dosing. Exposure pharmacokinetic measures were greater than the therapeutic level projected from in vitro studies of TBR-652.

"This Phase I study provides further clinical support for the continued development of TBR-652 in the treatment of HIV. We are very encouraged by the excellent exposure results from the study and look forward to results from ongoing trials," said James Sapirstein, CEO.

These data were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 12-15, 2009 in San Francisco, California. The poster presentation can be viewed at www.tobiratherapeutics.com.

About Tobira Therapeutics Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disea
'/>"/>

SOURCE Tobira Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
2. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
3. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics Board of Directors as Chair
6. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
7. PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
8. /C O R R E C T I O N -- Clinical Therapeutics/
9. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
11. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MD (PRWEB) July 28, 2014 ... personalized medicine, will be exhibiting data and research conducted ... International Spine Intervention Society’s (ISIS) 22nd Annual ... 3rd, at the Hyatt Regency, in Orlando, Florida. ... knowledge and clinical competence of physicians who care for ...
(Date:7/28/2014)... DALLAS , July 28, 2014 /PRNewswire/ ... research report  "Microbial Identification Market by Products (Consumables, Instruments, ... & Beverages), End User (Detection, Characterization) - ... global Microbial Identification Market is estimated at ... to reach $1,194.1 Million by 2019, growing ...
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
(Date:7/28/2014)... 28, 2014 The global market for ... 2020, according to a new study by Grand View ... demand for effective vaccines and drugs in an attempt ... needs is expected to drive market demand over the ... agricultural productivity via the use of genetically engineered seeds ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... 12 VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular disease, announced today that,James G. Stewart, ... present a company update at the Fourth Annual Noble ... 19, 2008 at the Loews Lake,Las Vegas Resort in ...
... and Webcast on Monday, August 18, 2008, ... Beginning at 1:00 PM Eastern Time, LIVINGSTON, ... recognized leader in,advanced injection technologies, today announced that it plans to ... 2008 on the morning,of Thursday, August 14, 2008., Milestone Scientific ...
... DSM Biologics and MorphoSys,AG (Frankfurt Stock Exchange: ... signing of a Biopharmaceutical Manufacturing Agreement,covering process ... is a,fully human HuCAL(R) antibody, directed against ... multiple myeloma. DSM Biologics will manufacture,MOR202 in ...
Cached Biology Technology:VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference 2Milestone to Report Results for 2008 Second Quarter on Thursday, August 14, 2008 2DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 2DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 3
(Date:7/28/2014)... Rice University researchers are using magnetic beads and ... can be used as microscale models for polymer macromolecules. ... introduced as theory in the 1950s, can be made ... be of interest to materials scientists who study the ... Rice chemical and biomolecular engineer Sibani Lisa Biswal and ...
(Date:7/28/2014)... killers to prevent and treat HIV infection has been ... these molecules can arouse as they get rid of ... the Weizmann Institute and the National Institutes of Health ... molecules interferons around the time of infection ... disease. Their research appeared in Nature . ...
(Date:7/28/2014)... explorer Roald Amundsen became the first man to reach ... 100 years later, an international team of scientists led ... have proven that air pollution from industrial activities arrived ... collected from widely spaced locations around the Antarctic continent, ... accurate and precise reconstruction to date of lead pollution ...
Breaking Biology News(10 mins):Seeing is bead-lieving 2Interfering with interferon 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... are losing about 1.6 million tonnes of carbon per year ... economy and carbon accounts, according to new research.,Top soil is ... away by events such as the ,Red Dawn, in Sydney ... the atmosphere it changes the amount and location of soil ...
... Improved diagnosis for people afflicted with carpal tunnel syndrome ... is the goal of a research collaboration led by an ... Clinic physician. Marco Santello and Mark Ross were recently ... Medicine to advance their effort to quantify the effects of ...
... help determine the vulnerability of public-supply wells to contamination. ... into which contaminants in an aquifer might reach a ... might arrive. About one-third of the U.S. population ... the understanding of the vulnerability of public-supply wells to ...
Cached Biology News:Soil carbon 'blowing in the wind' 2ASU-Mayo research project targets carpal tunnel syndrome diagnosis 2New insight on vulnerability of public-supply wells to contamination 2
Modified and insect cell culture tested....
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Mycoplasma and virus tested...
Edited by Benjamin Lewin (1997) • This book gives an integrated account of the structure and function of genes in both prokaryotic organisms and is thoroughly up to date with the latest thinking...
Biology Products: